Drugs / EDP-305
Trials 10
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2021-10-04 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs enanta.com ↗ |
| 2020-08-28 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress™ 2020 enanta.com ↗
Phase 2a ARGON-1 Study for FXR Agonist EDP-305 Targeting NASH, Showing Significant Alanine Transaminase and Liver Fat Content Reduction |
| 2020-08-20 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020 enanta.com ↗
EDP-305, A Non-Bile Acid Farnesoid X Receptor (FXR) Agonist, Showed Statistically Significant Improvements in Liver Biochemistry and Hepatic Steatosis in the Phase 2a ARGON-1 Study |
| 2020-05-06 | Enanta Pharmaceuticals, Inc | Results Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis enanta.com ↗
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its INTREPID Phase 2 study of EDP-305, a Farnesoid X receptor (FXR), in subjects with primary biliary cholangitis (PBC). |
| 2019-11-11 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019 enanta.com ↗
A NOVEL NON-BILE ACID FXR AGONIST EDP-305 PREVENTS PROGRESSION TO CIRRHOSIS IN THIOACETAMIDE-INDUCED MODEL IN RATS |
| 2019-09-25 | Enanta Pharmaceuticals, Inc | Results Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH enanta.com ↗
The study’s primary endpoint was achieved with a statistically significant ALT reduction of 28 U/L in the EDP-305 2.5mg arm versus 15 U/L in the placebo arm at week 12 (p=0.049). |
| 2017-12-21 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Data Presentations at the 2018 NASH-TAG Conference enanta.com ↗
treatment with EDP-305 had a significant therapeutic effect on NASH progression in NASH mouse models, and resulted in decreased liver steatosis, hepatocyte ballooning, and total non-alcoholic fatty liver disease score (NAS). |
| 2017-10-23 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Positive Phase 1 a/b Clinical Results for its Lead FXR Agonist, EDP-305 enanta.com ↗
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a chemistry-driven biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced positive results from its Phase 1 clinical study of EDP-305, Enanta’s lead FXR agonist for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). |
| 2017-10-20 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017 enanta.com ↗
“A novel FXR agonist EDP-305 potently suppresses hepatic stellate cell activation and hepatic fibrosis in chronic mouse models of biliary and metabolic liver disease” |
| 2017-04-19 | Enanta Pharmaceuticals, Inc | Results Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017 enanta.com ↗
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data from its lead FXR agonist candidate EDP-305 for NASH and PBC. |
| 2017-04-05 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017 enanta.com ↗
Three poster presentations will demonstrate that EDP-305 is a potent Farnesoid X Receptor (FXR) agonist that has been shown to reduce fibrosis progression and improve non-alcoholic fatty liver disease (NAFLD) activity scores (NAS) in a variety of preclinical models. |
| 2017-01-06 | Enanta Pharmaceuticals, Inc | Results Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference enanta.com ↗
New in vivo data to be presented demonstrating EDP-305 improved pre-established liver injury and hepatic fibrosis in an MCD-induced model of steatohepatitis in mice1 |
| 2017-01-04 | Enanta Pharmaceuticals, Inc | Regulatory FDA Grants Fast Track Designation to Enanta’s FXR Agonist Candidate, EDP-305, for the treatment of NASH with Liver Fibrosis enanta.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted Enanta’s drug candidate EDP-305, an FXR agonist, Fast Track designation for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis. |
| 2016-11-11 | Enanta Pharmaceuticals, Inc | Results Enanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2016 enanta.com ↗
Data demonstrated that EDP-305 reduced liver fibrosis in CDAHFD and BDL rodent models of NASH. |
All press releases naming this drug 17 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-305 | “of Orally Administered EDP-305 to Evaluate” NCT02918929 ↗ |
| Action | Activate | “investigational novel FXR agonist, EDP-305” NCT04378010 ↗ |
| Route | Oral | “orally administered doses of EDP-305” NCT02918929 ↗ |